[go: up one dir, main page]

AU4762893A - Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases. - Google Patents

Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.

Info

Publication number
AU4762893A
AU4762893A AU47628/93A AU4762893A AU4762893A AU 4762893 A AU4762893 A AU 4762893A AU 47628/93 A AU47628/93 A AU 47628/93A AU 4762893 A AU4762893 A AU 4762893A AU 4762893 A AU4762893 A AU 4762893A
Authority
AU
Australia
Prior art keywords
hla
treatment
autoimmune diseases
blocking peptides
associated autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47628/93A
Inventor
Rene Rudolf Pieter De Vries
Annemieke Geluk
Thomas Henricus Maria Ottenhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Original Assignee
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden filed Critical Universiteit Leiden
Publication of AU4762893A publication Critical patent/AU4762893A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU47628/93A 1992-07-15 1993-07-14 Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases. Abandoned AU4762893A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92201985 1992-07-15
EP92201985 1992-07-15
PCT/NL1993/000151 WO1994002509A1 (en) 1992-07-15 1993-07-14 Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.

Publications (1)

Publication Number Publication Date
AU4762893A true AU4762893A (en) 1994-02-14

Family

ID=8210744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47628/93A Abandoned AU4762893A (en) 1992-07-15 1993-07-14 Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.

Country Status (2)

Country Link
AU (1) AU4762893A (en)
WO (1) WO1994002509A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232522B1 (en) 1990-01-31 2001-05-15 Oklahoma Medical Research Foundation Non-human animal model for systemic lupus erythematosis
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
US5874405A (en) * 1994-12-16 1999-02-23 Birnbaum; Gary Heat shock protein peptides that share sequences with cyclic nucleotide phosphodiesterase and methods for modulating autoimmune central nervous system disease
FR2736831B1 (en) * 1995-07-19 1997-08-22 Centre Nat Rech Scient NUCLEOTIDE AND PEPTIDE SEQUENCES FOR THE TREATMENT OF MYASTHENIA
AU1749597A (en) * 1996-01-19 1997-08-11 Virginia Mason Research Center Allele-specific peptide epitope strategy for vaccine development
US7273613B1 (en) 1997-01-13 2007-09-25 The Board of Regents, The University of Oklahoma Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
WO2003063759A2 (en) 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (en) * 1986-09-09 1988-04-05 Nederlanden Staat USE OF A PEPTIDE FOR THE PREPARATION OF PREPARATIONS FOR LIGHTING, TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASES, IN PARTICULAR ARTHRITIC CONDITIONS, COMPOUNDS RELATED TO THIS PEPTIDE, AND PHARMACEUTICAL AND DIAGNOSTIC PREPARATORY.

Also Published As

Publication number Publication date
WO1994002509A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
ZA971259B (en) Antimicrobial peptides and methods of use.
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
PH31600A (en) Methods of inhibiting atrophy of the skin and vagina.
AU4786093A (en) Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression
EP0445801A3 (en) Peptide and its use
ZA935575B (en) Therapeutic agent and its use.
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
AU5681694A (en) Use of thioureleylenes and thiabendazole in autoimmune diseases
AU1636492A (en) Peptides having thrombospondin-like activity and their therapeutic use
AU4100593A (en) Iminoalcohol-oxazolidine mixtures and their use
AU6761294A (en) Cell surface protein expressed on human cortical thymocyte and their use
HUP9801680A3 (en) Peptides and remedy for autoimmune diseases comprising the same
AU6809594A (en) Colletotrichum and use thereof
AU1031397A (en) Human peptide circulating in the blood and possessing insulinotropic properties
NZ239183A (en) Peptides antagonistic against bombesin or like proteins and their use in the treatment of disease
AU6491890A (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
EP0841393A4 (en) HUMAN GALECTIN-4-LIKE PROTEIN AND cDNA ENCODING THE SAME
AU7352396A (en) Use of protein S-100b in medicines and medicines containing the protein S-100-b
AU5042890A (en) Composition and treatment with peptide combinations
EP0863204A4 (en) Human cyclin i and gene encoding the same
GB9302553D0 (en) Pharmaceutical preparations and their manufacture and use
AU8603591A (en) Peptide and its use
EP0540575A4 (en) Human meg-csf protein and methods
ZA932233B (en) Peptide T and related peptides in the treatment of inflammation including multiple sclerosis
AU7078094A (en) Allatostatins and their use